FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma.
Singh S, Bradford D, Chatterjee S, Li X, Aungst SL, Skinner AM, Miller CP, Kim-McOlash S, Fourie Zirkelbach J, Xiong Y, Bi Y, Wang YH, Yang Y, Sun J, Kraft J, Charlab R, Shord SS, Tang S, Scepura B, Bulatao I, Udoka O, Saber H, Rahman NA, Pazdur R, Singh H, Donoghue M, Drezner N.
Singh S, et al. Among authors: shord ss.
Clin Cancer Res. 2025 Apr 14;31(8):1383-1389. doi: 10.1158/1078-0432.CCR-24-3439.
Clin Cancer Res. 2025.
PMID: 39808502
Free PMC article.
Clinical Trial.